GeorgeR.BlumenscheinJr.MD

PubMed

• Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From-Mutant NSCLC Informs Potential Therapeutic Targets.
  Bingnan Zhang, Whitney Lewis, C Allison Stewart, Benjamin B Morris, Luisa M Solis, Alejandra Serrano, Yuanxin Xi, Qi Wang, Elyse R Lopez, Kyle Concannon, Simon Heeke, ...> ;JTO Clinical and Research Reports. 2024 Feb 1
• 7 citations
  The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
  Jason J Luke, Manish R Patel, George R Blumenschein, Erika Hamilton, Bartosz Chmielowski, Susanna V Ulahannan, Roisin M Connolly, Cesar A Santa-Maria, Jie Wang, Shakee...> ;Nature Medicine. 2023 Nov 1
• The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.
  Joanne B Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A Masters, George R Blumenschein, Joe Y Chang, Bo Lu, Adam P Dicker, Jeffrey A Bogart, Yolanda I Garces, Samir Nara...> ;Cancer Research Communications. 2023 Oct 11
• 1 citations
  Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
  Kaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, Ziping T Li, Lingzhi Hong, Natalie Vokes, Yasir Y Elamin, Celyne Bueno Hume, Ferdinandos Skoulidis, Carl M Gay, George B...> ;JTO Clinical and Research Reports. 2023 Aug 1
• 21 citations
  Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an op...
  Joe Y Chang, Steven H Lin, Wenli Dong, Zhongxing Liao, Saumil J Gandhi, Carl M Gay, Jianjun Zhang, Stephen G Chun, Yasir Y Elamin, Frank V Fossella, George Blumenschei...> ;Lancet. 2023 Sep 9
• 21 citations
  Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
  Marcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi H...> ;Cancer Discovery. 2023 Jul 7
• 3 citations
  Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-r...
  Mehmet Altan, Yan Wang, Juhee Song, James Welsh, Chad Tang, Nandita Guha-Thakurta, George R Blumenschein, Brett W Carter, Jeffrey S Wefel, Amol J Ghia, Debra N Yeboa, ...> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
• A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
  Blessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K Sood, Jordi Rodon, Daniel D Karp, George Blumenschein, Scott Kopetz, Shu...> ;The Oncologist. 2023 Dec 11
• 1 citations
  Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
  Mehmet Altan, Janet Tu, Denái R Milton, Bulent Yilmaz, Yanyan Tian, Frank V Fossella, Frank E Mott, George R Blumenschein, Bettzy Stephen, Daniel D Karp, Funda Meric-B...> ;Cancer. 2023 Sep 1
• 8 citations
  Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
  Renata Ferrarotto, Luana G Sousa, Lei Feng, Frank Mott, George Blumenschein, Mehmet Altan, Diana Bell, Flavia Bonini, Kaiyi Li, Mario L Marques-Piubelli, Eduardo A Dal...> ;Journal of Clinical Oncology. 2023 May 20
• 3 citations
  Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-s...
  Liza C Villaruz, George R Blumenschein Jr, Gregory A Otterson, Ticiana A Leal> ;Cancer. 2023 May 1
• 1 citations
  Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
  Cliff Molife, Alan Brnabic, Victoria J Stefaniak, Mark A Belger, Kristi Gruver, Jing V Chen, Saman Souri, George R Blumenschein Jr> ;Immunotherapy. 2023 Mar 1
• 24 citations
  Autologous T cell therapy for MAGE-A4solid cancers in HLA-A*02patients: a phase 1 trial.
  David S Hong, Brian A Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L Johnson, Anthony J Olszanski, Jeffrey M Clarke, Dejka Araujo, George R Blumenschein Jr, Pa...> ;Nature Medicine. 2023 Jan 1
• 5 citations
  Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.
  Yufei Liu, Luyang Yao, Neda Kalhor, Brett W Carter, Mehmet Altan, George Blumenschein, Lauren A Byers, Frank Fossella, Don L Gibbons, Jonathan M Kurie, Charles Lu, Fer...> ;Lung Cancer. 2022 Dec 1
• 11 citations
  Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC.
  Wang Jing, Ting Xu, Lirong Wu, Pablo B Lopez, Clemens Grassberger, Susannah G Ellsworth, Radhe Mohan, Brian P Hobbs, George R Blumenschein, Janet Tu, Mehmet Altan, Per...> ;JTO Clinical and Research Reports. 2022 Sep 1
• 2 citations
  Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer.
  Misako Nagasaka, Cliff Molife, Zhanglin Lin Cui, Victoria Stefaniak, Xiaohong Li, Sangmi Kim, Hsui-Yung Lee, Julia Beyrer, George Blumenschein> ;Future Oncology. 2022 May 1
• 32 citations
  Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
  Sang T Kim, Yanshuo Chu, Mercy Misoi, Maria E Suarez-Almazor, Jean H Tayar, Huifang Lu, Maryam Buni, Jordan Kramer, Emma Rodriguez, Zulekha Hussain, Sattva S Neelapu, ...> ;Nature Communications. 2022 Apr 12
• 17 citations
  Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
  Maura L Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin J Harrington, Stefan Kasper, Everett E Vokes, Caroline Eve...> ;The Oncologist. 2022 Mar 4
• 5 citations
  Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.
  Steven H Lin, Heather Y Lin, Vivek Verma, Meng Xu-Welliver, Peter F Thall, Luyang Yao, Peter Y Kim, Dan S Gombos, Jitesh D Kawedia, Ritsuko Komaki, Daniel R Gomez, Quy...> ;Cancer Treatment and Research Communications. 2022 Jan 1
• 17 citations
  Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10advanced non-small cell lung cancer.
  George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, Victor Moreno, Justin Gainor, Martin J Edelman, John V Heymach, Ramaswamy Govindan, Carlos Bachier, Ber...> ;Journal for Immunotherapy of Cancer. 2022 Jan 1
• 38 citations
  Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
  Yasir Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Don L. Gibbons, Frank V. Fossella, Vincent K. Lam, Anisha B. Patel, Marcelo V. Negrao, Xiuning Le,...> ;Journal of Clinical Oncology. 2021 Sep 22
• 9 citations
  Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic...
  Hai T. Tran, Vincent K. Lam, Yasir Elamin, Lingzhi Hong, Rivkah Colen, Nabil Elshafeey, Islam Hassan, Mehmet Altan, George R. Blumenschein, Waree Rinsurongkawong, Melv...> ;JCO Precision Oncology. 2021 Aug 5
• 6 citations
  Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
  Renata Ferrarotto, Luana Guimarães Sousa, Yun Qing, Diana Kaya, Bettzy Stephen, Dipti Jain, Diana Bell, Shubham Pant, Apostolia Maria Tsimberidou, Filip Janku, George ...> ;Advances in Therapy. 2021 Jul 9
• 39 citations
  High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial.
  Roshal R. Patel, Kewen He, Hampartsoum B. Barsoumian, Joe Y. Chang, Chad Tang, Vivek Verma, Nathan Comeaux, Stephen G. Chun, Saumil Gandhi, Mylene T. Truong, Jeremy J....> ;Radiotherapy and Oncology. 2021 Jul 5
• 300 citations
  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
  Tina Cascone, William N. William, Annikka Weissferdt, Cheuk Hong Leung, Heather Lin, Apar Pataer, Myrna C.B. Godoy, Brett W. Carter, Lorenzo Federico, Alexandre Reuben...> ;Nature Medicine. 2021 Feb 18
• Join now to see all